Nanomedicine: Is the wave cresting?

Nature Reviews Drug Discovery

Volumn 12, Issue 3, 2013, Pages 171-172

  Juliano, Rudy ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DOXORUBICIN; NANOPARTICLE; PACLITAXEL;

BREAST CANCER; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; ENDOTHELIUM CELL; FUNDING; HUMAN; MEDICAL RESEARCH; NANOMEDICINE; NOTE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; REIMBURSEMENT;

HUMANS; NANOMEDICINE; NANOPARTICLES; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84875178629     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3958     Document Type: Note

References (5)

1. Venditto, V. J. & Szoka, F. C. Jr. Cancer nanomedicines: So many papers so few drugs! Adv. Drug Deliv. Rev. 1 Oct 2012 (doi:10.1016/j.addr.2012. 09.038).
2. Duncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 8, 2101-2141 (2011).
3. Chauhan, V. et al. Delivery of molecular and nanoscale medicine to tumors: barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298 (2011).
4. Cheng, Z. et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 (2012).
5. Rugo, H. S. et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J. Clin. Oncol. Abstr. S30, CRA1002 (2012).